Page 136 - Eceptor News Today

Researchers in Australia have evaluated the vaccine candidature of HexaPro S protein subunit vaccine against SARS-CoV-2.

They might look like cells and act like cells. But a new potential COVID-19 treatment is actually a cleverly disguised trickster, which attracts viruses and binds them, rendering them inactive.

The human body has millions of unique B and T cells that roam the body, looking for microbial invaders. These immune cells' ability to recognize harmful microbes is critical to successfully fighting off infection.

A new chimeric antigen receptor (CAR) T-cell product had an acceptable safety profile and showed early signs of efficacy as a monotherapy and in combination with an mRNA vaccine in patients with solid tumors, according to preliminary data from a phase I/II clinical trial presented during the AACR Annual Meeting 2022, held April 8-13.

A new study depicted plant-based biologically active antiviral agents that are effective against SARS-CoV-2 infection.

Researchers assess the impact of interval administration of LD-IL-2 was examined in 18 T1D patients who received a three-day dosing interval.

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

An innovative proteomics-based model that predicts the risk of cardiovascular events with higher accuracy than current clinical models.

Researchers evaluated the human antibody response to the NTD of the S protein by investigating a group of individuals who had previously been infected with SARS-CoV-2 or who had received an mRNA vaccine.

Researchers identified an ultralong bovine antibody that neutralizes SARS-CoV-2 and SARS-CoV.